Nektar Therapeutics (NASDAQ:NKTR) had its price target hoisted by Jefferies Group from $2.12 to $88.00 in a research report report published on Tuesday morning, The Fly reports. Jefferies Group currently has a buy rating on the biopharmaceutical company’s stock. Jefferies Group also issued estimates for Nektar Therapeutics’ Q4 2017 earnings at ($0.43) EPS, FY2017 earnings at ($0.84) EPS, FY2018 earnings at ($0.82) EPS, FY2019 earnings at ($1.01) EPS, FY2020 earnings at ($0.77) EPS, FY2021 earnings at ($0.67) EPS and FY2022 earnings at ($0.67) EPS.

Other equities research analysts also recently issued research reports about the company. Canaccord Genuity reissued a buy rating and set a $80.00 target price (up previously from $50.00) on shares of Nektar Therapeutics in a report on Wednesday, January 10th. Mizuho reissued a buy rating and set a $45.00 target price (up previously from $30.00) on shares of Nektar Therapeutics in a report on Wednesday, November 8th. Zacks Investment Research downgraded Nektar Therapeutics from a hold rating to a sell rating in a report on Tuesday, January 9th. JPMorgan Chase & Co. reissued a buy rating and set a $44.00 target price on shares of Nektar Therapeutics in a report on Monday, November 13th. Finally, Cowen initiated coverage on Nektar Therapeutics in a report on Tuesday, November 7th. They set an outperform rating for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus target price of $42.50.

Nektar Therapeutics (NKTR) traded up $1.43 on Tuesday, hitting $71.59. The stock had a trading volume of 3,699,340 shares, compared to its average volume of 2,768,031. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $75.33. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91. The firm has a market capitalization of $11,120.00, a P/E ratio of -100.83 and a beta of 1.81.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The company had revenue of $152.90 million during the quarter, compared to the consensus estimate of $126.50 million. During the same quarter last year, the firm earned ($0.32) earnings per share. The company’s revenue was up 321.2% on a year-over-year basis. sell-side analysts expect that Nektar Therapeutics will post -0.76 EPS for the current year.

In other Nektar Therapeutics news, Director Christopher A. Kuebler sold 30,000 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the transaction, the director now owns 70,500 shares of the company’s stock, valued at $4,135,530. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Howard W. Robin sold 83,333 shares of the business’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $55.69, for a total value of $4,640,814.77. Following the transaction, the chief executive officer now directly owns 272,768 shares of the company’s stock, valued at approximately $15,190,449.92. The disclosure for this sale can be found here. In the last ninety days, insiders sold 614,017 shares of company stock valued at $20,587,527. 6.10% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. raised its stake in Nektar Therapeutics by 14.1% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 802,474 shares of the biopharmaceutical company’s stock worth $47,924,000 after acquiring an additional 99,192 shares in the last quarter. Sicart Associates LLC acquired a new position in Nektar Therapeutics during the fourth quarter worth about $245,000. Louisiana State Employees Retirement System raised its stake in Nektar Therapeutics by 7.0% during the fourth quarter. Louisiana State Employees Retirement System now owns 67,700 shares of the biopharmaceutical company’s stock worth $4,043,000 after acquiring an additional 4,400 shares in the last quarter. Rubric Capital Management LP acquired a new position in Nektar Therapeutics during the third quarter worth about $23,924,000. Finally, GSA Capital Partners LLP acquired a new position in Nektar Therapeutics during the third quarter worth about $1,454,000. 96.01% of the stock is owned by hedge funds and other institutional investors.

WARNING: This report was reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.watchlistnews.com/jefferies-group-raises-nektar-therapeutics-nktr-price-target-to-88-00/1814305.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

The Fly

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.